UroGen Launches LG-UTUC Luminaries, Honors Leaders in Care for 6,000-7,000 Annual Patients
UroGen Pharma launched the LG-UTUC Luminaries initiative to honor clinicians and institutions advancing kidney-sparing low-grade upper tract urothelial cancer care, a disease affecting 6,000-7,000 U.S. patients annually and representing 40% of UTUC cases. The program’s inaugural honoree is Dr. Saum Ghodoussipour of Rutgers Cancer Institute for his research and patient-centered care leadership.
1. Initiative Launch and Purpose
UroGen Pharma announced the launch of its LG-UTUC Luminaries initiative to recognize clinicians and institutions demonstrating excellence in low-grade upper tract urothelial cancer care. The program aims to foster collaboration, promote guideline-recommended kidney-sparing treatments and elevate clinical leadership across the urology community.
2. Scope of LG-UTUC Disease
Low-grade upper tract urothelial cancer affects an estimated 6,000-7,000 patients in the U.S. each year, accounting for about 40% of UTUC diagnoses. Although typically noninvasive, LG-UTUC frequently recurs and often requires repeated endoscopic procedures or radical surgery, underscoring the need for kidney-sparing care pathways.
3. First LG-UTUC Luminaries Honoree
The initiative’s inaugural honoree is Dr. Saum Ghodoussipour, Director of the Bladder and Urothelial Cancer Program at Rutgers Cancer Institute, recognized for his research contributions and patient-centered kidney-sparing management. Future honorees will be selected for their leadership in treatment, research participation and physician training in LG-UTUC care.
4. Strategic Implications for UroGen
By highlighting clinical leaders and institutions, UroGen seeks to strengthen adoption of its RTGel reverse-thermal hydrogel platform, designed to improve local therapy exposure in the urinary tract. This initiative supports UroGen’s broader strategy to drive evidence-based kidney-sparing treatment options and foster long-term partnerships within the urology field.